# Rad2Nivo (NCT04109729)

> Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer

No report yet. It can be ordered.

- Drugs tested: nivolumab plus radium-223
- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04109729
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Utah
- Conditions: Metastatic Castration-resistant Prostate Cancer
- Interventions: Nivolumab; Radium-223
- Enrollment: 39
- Primary outcome: To assess the frequency of grade 3 or greater non-hematologic treatment-emergent adverse events when combining nivolumab with Radium-223
- Primary outcome: To assess the ctDNA reduction after 6 weeks of nivolumab treatment.

## Indexed commentary on Rad2Nivo so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=rad2nivo-nct04109729